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Eﬃcient in vitro diﬀerentiation into speciﬁc cell types is more important than ever after the breakthrough in nuclear
reprogramming of somatic cells and its potential for disease modeling and drug screening. Key success factors for neuronal
diﬀerentiation are the yield of desired neuronal marker expression, reproducibility, length, and cost. Three main neuronal
diﬀerentiation approaches are stromal-induced neuronal diﬀerentiation, embryoid body (EB) diﬀerentiation, and direct neuronal
diﬀerentiation. Here, we describe our neurodiﬀerentiation protocol using small molecules that very eﬃciently promote neural
induction in a 5-stage EB protocol from six induced pluripotent stem cells (iPSC) lines from patients with Parkinson’s disease and
controls.ThisprotocolgeneratesneuralprecursorsusingDorsomorphinandSB431542andfurthermaturationintodopaminergic
neurons by replacing sonic hedgehog with purmorphamine or smoothened agonist. The advantage of this approach is that all
patient-speciﬁc iPSC lines tested in this study were successfully and consistently coaxed into the neural lineage.
1.Introduction
The advent of nuclear reprogramming of somatic cells into
induced pluripotent stem cells (iPSCs) for in vitro disease
modelingalsoacceleratedtheﬁeldofdiﬀerentiationintospe-
cialized cell types. Diﬀerentiation into speciﬁc lineages had
its primary place to provide a resource for cell replacement
therapies [1]. These specialized diﬀerentiated cells were in
general derived from a small number of “approved” human
embryonic stem cell lines [2, 3].
Patient-speciﬁc iPSC-derived diﬀerentiated cells have
now become an attractive tool to study disease mechanisms
on a human background and are a vanguard into a new
era of science and potentially personalized medicine. In
particular for monogenic forms of disease, patient-derived
iPSCshavealreadybeenshowntorecapitulateknowndisease
mechanisms,asshowninspinalmuscularatrophy[4],fragile
X syndrome [5], progeria syndrome [6], and several genetic
forms of Parkinson disease (PD) like LRRK2 [7], PINK1 [8],
SNCA [9], and GBA [10]. This novel approach of disease
modeling becomes very attractive for drug screening and
discovery [11, 12].
One of the challenges is to diﬀerentiate these patient-
derived iPSCs into the desired specialized cell type of
interest. For neuronal diﬀerentiation, there were three main
approaches developed in the last decade to derive dopamin-
ergic neurons [13–15]. The ﬁrst method is stromal-induced
neuronal diﬀerentiation, termed stromal cell-derived induc-
ing activity (SDIA) [16, 17]. The concept is that mouse
stromal cells such as PA6 or MS5 or midbrain astrocytes
were used to coax the regionalization of stem cells. The
disadvantage of this method is the variability of stromal cells
and unknown factors; furthermore, this protocol is overall
lengthyandtakesabout40–60daysinvitro.Thesecondmain
approach is embryoid body (EB)/neurosphere-mediated
diﬀerentiation [18, 19], caveats are clonal expansion of sub-
groupofcellsandpotentialforebrainspeciﬁcation.However,
the usefulness of neuronal precursors (NPCs) is that they
can be expanded, cryopreserved, and be a starting pool
for ﬁnal maturation. NPCs are also important for scientiﬁc
questions of developmental phenotypes related to disease.
The third approach of direct neuronal diﬀerentiation utilizes
high-density monolayer ESC/iPSC cultures via ﬂoor-plate
formationwhichgivesthepromiseofshorteningthetimefor2 Stem Cells International
neuronal development while reaching high diﬀerentiation
eﬃciency of midbrain dopaminergic neurons [15] and show
excellentsurvivalandfunctionalbeneﬁtwhichgiveshopefor
regenerative therapies in Parkinson’s disease [20].
Here, we describe a 5-stage EB diﬀerentiation approach
using small molecules to enhance neural induction con-
sistently in patient and control iPSC lines. In addition,
we substituted sonic hedgehog (Shh) with purmorphamine
(Pur) and/or smoothened agonist (SAG) to reduce cost for
the ﬁnal maturation and have shown comparable results
between Shh and these small molecules. We have made
considerable progress in consistency and reproducibility of
this process; however, there is still a challenge of improving
the overall yield of region-speciﬁc dopaminergic neurons.
2.MaterialsandMethods
2.1. Skin Biopsies of Patient and Control Subjects. Skin punch
biopsies (4-mm circular) were taken from all individuals
employing a standard punch biopsy [21]. All biopsies were
taken from the upper inner arm, an area that is mostly
unexposed to direct sunlight. We used a standard skin
explant culture technique by cutting the biopsy tissue into
12–15 pieces and placed 2-3 pieces into one well of a
gelatinized6-wellplatein1mLofhigh-glucoseDMEM,20%
fetal bovine serum, 1x nonessential aminoacids (NEAA), 1x
penicillin streptomycin (P/S), 1x L-glutamine (Glu) (all were
purchased from Invitrogen, Carlsbad, CA). Outgrowth of
keratinocyteswasﬁrstnoted2–5daysafterplating.Cellswere
expanded using standard tissue culture techniques, cells were
passaged upon conﬂuency using trypsin/EDTA (Invitrogen)
and 15–20 million cells. Miocells were cryopreserved for
banking. This study and protocol had Institutional Review
Board approval and all subjects gave written informed
consent for this study. Clinical information on the patients
is provided in Supplementary Table 1 (see supplementary
materials available at doi:10.1155/2012/140427).
2.2. Generation of iPSC. All iPSCs were derived using a
retroviralsystemtodeliverfourgenesencodingOCT4,KLF4,
SOX2 and cMYC (from Addgene plasmids 17217, 17218,
17219, 17220, http://www.addgene.org/) using published
protocols [22, 23]. All lines have been characterized for
pluripotency, diﬀerentiation potential into three germ layers,
are karyotypically normal and genotype-match the parental
ﬁbroblasts, (see Supplementary Table 2). IPSC line 1761 was
previously described and characterized in Nguyen et al. 2011
[7].
2.3.iPSCMaintenanceandPropagation. iPSCswerecultured
and maintained on mitomycin C inactivated mouse embry-
onic ﬁbroblasts (iMEF) (EMD Millipore Cat. No. PMEF-
CF) in hESC media containing DMEM/F12, 20% knockout
serum replacement (Invitrogen, Cat. No. 10828028), 1x
NEAA, 1x P/S, 0.1% β-Mercaptoethanol (Invitrogen, Cat.
No. 21985023), 0.5x L-Glu and 6ng/mL of basic ﬁbroblast
growth factor (FGF2) (Cat. No. 233-FB, R&D Systems,
Minneapolis, MN). Cells were split every week manually
without enzymatic treatment.
2.4. Generation and Maintenance of Neural Progenitor Cells
(NPCs). To derive NPCs, iPSC colonies were harvested
using 1mg/mL of collagenase IV (Invitrogen, Cat. No.
174104019). After about 1hr, when all colonies lifted up
completely from culture dish, colonies were transferred to
10cm bacterial petri dishes (BD Bioscience, Bedford, MA).
Forming embryoid bodies (EB) was cultured in suspension
with agitation on rocker (Rocker II Model 260350, Boekel
Scientiﬁc, Feasterville, PA) for 4 days in EB media, which
consisted of hESC media minus FGF2 with or without 5μM
dorsomorphin (Dor) (Sigma, St Louis, MO, Cat. No. P5499)
and 10μM SB431542 (SB) (Tocris Bioscience, Ellisville, MO,
Cat. No. 1614).
Next, EBs were cultured for additional 2-3 days with
agitation in neural induction media (NIM) consisting of
DMEM/F12 (Invitrogen, Cat. No. 12500, powder form), 1x
NEAA, 0.5x L-Glu, and freshly made and sterile ﬁltered N2,
which contained 1.55g/L glucose (Sigma, Cat. No. G7021),
2g/L sodium bicarbonate (Sigma, Cat. No. S5761), 100μM
putrescine (Sigma, Cat. No. P5780), 30nM sodium selenite
(Sigma, Cat. No. S9133), 20nM progesterone (Sigma, Cat.
No. P8783), 0.1mg/mL transferrin (Sigma, Cat. No. T0665),
0.025mg/mL insulin (Sigma, Cat. No. I6634) and FGF2
(20ng/mL). Cell culture plates were coated with Geltrex
(Invitrogen, Cat. No. 12760021), media changed every day.
Neural rosettes were formed in 2–5 days in adherent culture.
To obtain a pure population of NPCs, rosettes were
manuallyisolatedusingNo.15scalpelcuttinginsquareswith
distance to edges of colonies (Figure 3(F)). Dissected pieces
of rosettes were lifted using a pipette, replated onto Geltrex-
coated culture dishes and maintained in neural progenitor
cellmedia(NPCmedia)containingneurobasalmedia(Invit-
rogen, Cat. No. 21103049), 1x NEAA, 1x L-Glu, 1x P/S, 1x
B27 supplement (Invitrogen, Cat. No. 17504044), and FGF2
(20ng/mL). Manual isolation of rosettes as described above
was repeated once to obtain more pure population of NPCs.
Approximately 5–10 pieces of rosettes were dissociated into
single cells using Accutase (MP Biomedicals, Solon, OH,
Cat. No. 0910004). Cells were treated with Accutase for 2–
5 minutes until cells became round in shape, then the cells
were collected, centrifuged, resuspended in NPC media, and
plated onto one 96-well coated with Geltrex and cultured at
37◦C and 5% CO2. When conﬂuent, NPCs were split at a
ratio of 1:2 in single wells with larger surface area such as
48-well, 24-well, 12-well, and so forth in NPC media.
2.5. NPC Enrichment Using Anti PSA-NCAM Microbeads.
Formagneticbeadsorting,NPCsweretreatedwithAccutase,
collected, and passed through 30μm nylon mesh (pre-
separation ﬁlters, 30μm, Miltenyi Biotec Auburn, CA, Cat.
No. 130-041-407). The total cell number was approximately
107. Cell suspension was centrifuged at 300×gf o r1 0
minutes. Supernatant was aspirated completely and cell
pellet was resuspended in 60μLo fb u ﬀer (1x PBS, 2mM
EDTA (Ambion Inc, Austin, TX, Cat. No. AM9260G) andStem Cells International 3
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Figure 1: Schematic summary of the diﬀerentiation conditions used in the generation of dopaminergic neurons (a) Schematic diagram
illustratingthediﬀerentstagesofNPCgenerationanddopaminergicneuronaldiﬀerentiation.Theabbreviationsare.Dor/SB:Dorsomorphin
and SB431542, EB: EB media, NIM: neural induction media, NPC: neural progenitor cell media, and DA1/DA2: medium for dopaminergic
diﬀerentiation. (b) Timeline shows the medium used at diﬀerent stages of NPCs and dopaminergic maturation and displays the sampling
dates for performing gene expression studies, such as qPCR, marker characterization (immunoﬂuorescence: IF), to analyze eﬃciency of
rosette formation and for quantitative studies of TUJ1 and TH immunoreactivity using stereology and ﬂow cytometry.
(a)
+Dor/SB
Control
PD
−Dor/SB
(b)
Figure 2: (a) Representative image of the quality of iPSC colonies used to produce EBs: distinct border with little to no diﬀerentiation. The
recommended size for EB formation should be double the size as the depicted colony, approximately 2mm in diameter. Scale bar 100μm( b )
In-control and PD-speciﬁc cell lines (Control and PD), EBs were lacking that compact structure and round borders when cultured without
Dor/SB; EBs were found to be round, uniform in the presence of Dor/SB.4 Stem Cells International
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Figure 3: Representative images of neural rosettes at diﬀerent stages (A–D). Neural rosettes after Dor/SB treatment at days 7–12, stage III of
the diﬀerentiation protocol (5x magniﬁcation). Arrows indicate boundary lines in the early and late stages of rosettes. (E) and (F) Manual
dissection of rosettes using scalpel are illustrated before (E) and after (F) cutting. (G and H) Arrows indicate the positions of neural rosettes
that were immunoreactive with Pax6 (green) (E) and Sox1 (red) (F). Scale bar represents 20μm. (i) There is a signiﬁcant diﬀerence in neural
rosette formation in all control and PD-speciﬁc EBs treated with Dor/SM compared to those with no Dor/SB treatment during stage II
(∗P<0.01). Data are presented as mean + standard error of the mean (SEM) compared to the controls (n = 3, except 1679, n = 2). P value
of each study was assessed by one-way ANOVA along with Newman-Keuls post-hoc analysis.
0.5% albumin from bovine serum (BSA) (Sigma, Cat.
No. A3294). Cells were mixed well and incubated for 10
minutes in the refrigerator (2−8◦C). Then, 20μL of anti-
PSA-NCAM microbeads (Miltenyi Biotech, Auburn, CA,
Cat.No.130-092-966)wereaddedtothemixture,mixedwell
with pipetting up and down, and incubated for 15 minutes
in the refrigerator (2−8◦C). Cells were washed by adding
2mL of buﬀer and centrifuged at 300×gf o r1 0m i n u t e s .
Supernatant was aspirated completely and cell pellet was
resuspended up to 108 cells in 500μLo fb u ﬀer. A MS column
(Miltenyi Biotec, Cat. No. 130-042-201) was placed in the
magnetic ﬁeld of a miniMACS separator (Miltenyi Biotec,
Cat. No. 130-042-102), rinsed with 500μLo fb u ﬀer three
times. Cell suspension was applied onto the column. The
column was washed with 500μLo fb u ﬀer three times again.
New buﬀer was added when the column reservoir was
empty. The column was removed from the separator and
placed on a 15mL BD Falcon conical tube (BD Bioscience,
352097). One mL of buﬀer was added onto the column and
magnetically labeled cells were ﬂushed out by ﬁrmly pushing
the plunger into the column. The eluted fraction was directly
enriched over a second column and the magnetic separation
procedure was repeated once by using a new MS column.
One mL of NPC media was added onto the column to ﬂush
outthemagneticallylabeledcells.Thenanother1mLofNPC
media was added and cell suspension was transferred to a
35mm Geltrex-coated culture dish.
2.6. Dopaminergic Diﬀerentiation of NPCs. Dopaminergic
diﬀerentiation was initiated by culturing NPCs on Geltrex-
coated culture dishes or glass coverslips (Fisher Scien-
tiﬁc, Pittsburg, PA, Cat. No. 12-545-80-12CIR-1) coated
with poly-L-ornithine (20μg/mL) (Sigma, Cat. No. P4957)Stem Cells International 5
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Figure 4: Quantitative gene expression analysis of PD and control lines with and without Dor/SB. Expression levels of neuroectoderm (Sox1
and Nestin), mesoderm (Brachyury), endoderm (GATA4), and pluripotent markers (Oct4) were assessed by quantitative PCR. The y-axis
represents means + SEM of relative expression levels of each gene in the EBs with Dor/SB relative to no Dor/SB treatment (∗P<0.01). Left
panel depicts lines from healthy donors; right panels depicts cell lines derived from patients with PD. Data are presented as mean + SEM
compared to the controls (n = 3, except 1679, n = 2). P-value of each study was assessed by one-way ANOVA along with Newman-Keuls
post-hoc analysis.6 Stem Cells International
Figure 5: Characterization of NPCs. (A) and (B) NPC morphology was observed under phase-contrast microscopy with 5x (A and 10x (B)
magniﬁcation. (C and D) NPCs expressed Nestin (green) (C) and Sox1 (red). (D) Nuclei were counterstained with DAPI (blue). Scale bar
represents 20μm.
at 37◦C for 4hrs and laminin (Sigma Cat. No. L2020)
(20μg/mL) at 4◦C overnight.
Dopaminergic diﬀerentiation in deﬁned media was initi-
ated by culturing ∼0.5 × 106 NPCs (in 35mm culture dish)
inDA1mediafor10daysinNeurobasalmediasupplemented
with1xNEAA,1xL-Glu,1xP/S,1xB27,FGF8b(100ng/mL)
(R&D Systems, Cat. No. 423-F8) and tested with either 2μM
Purmorphamine (Pur) (EMD Chemicals, Cat. No. 540220),
Gibbstown, NJ), 0.4mM SAG (Enzo Life Sciences, Farming-
dale, NY, Cat. No. ALX-270-426-M001) or 200ng/mL Sonic
Hedgehog, C24II (Shh) (R&D Systems, Cat. No. 1845-SH).
During these 10 days, when cells grew conﬂuent, they were
passaged with Accutase as described above and replated onto
aGeltrex-coatedplatesatcelldensityof∼80%.Lowerdensity
led to cell death.
Final maturation into dopaminergic neurons was carried
out in DA2 media containing neurobasal media supple-
mented with 1x NEAA, 1x L-Glutamine, 1x B27 supplement,
1x Penicillin-Streptomycin, 20ng/mL BDNF (R&D Systems,
Cat. No. 248-BD), 20ng/mL GDNF (R&D Systems, Cat.
No. 212-GD), and 1mM dibutyryl cAMP (Sigma, Cat.
No. D0627) for 20–30 days. Cells were not continued to
passage in DA2 media when the processes formed. Cells were
analyzed on day 30 of the maturation process.
2.7. Quantitative PCR (qPCR). EBs were collected on day 6
of EB formation before plating down for rosette formation.
Total RNA was extracted using a RNeasy Micro kit (Qiagen,
Valencia, CA) and 500ng RNA was used for reverse-
transcription into cDNA using the iScript cDNA Synthesis
Kit(BioRad,Hercules,CA).Totalreactionvolumewas20μL;
the resulting cDNA sample was diluted with 80μL of ultra-
pure water, and 5μL of the diluted cDNA sample was used
as template for qPCR ampliﬁcation. qPCR was performed
using ABI PRISM 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA). All reactions were run in
20μL reactions volume using SYBR Green PCR Master Mix
(Applied Biosystems) and 30pmol of each primer. qPCR
parameters were as follows: 2min at 50◦C; 10min at 95◦C;
40 cycles at 95◦C for 15sec, and at 60◦C for 1min. Data
were collected at 60◦C. All data were normalized to β-actin
expression and plotted as fold changes over samples from
EBs without Dor/SB. Primers of genes used in this study:
Sox1 (5 -GAGATTCATCTCAGGATTGAGATTCTA-3  and
5 -GGCCTACTGTAATCTTTTCTCCAC-3 ); Nestin (5 -
TGCGGGCTACTGAAAAGTTC-3  and 5 -AGGCTGAGG-
GACATCTTGAG-3 ); Brachyury (5 -AGGTACCCAACC-
CTGAGGA-3  and 5 -GCAGGTGAGTTGTCAGAATAG-
GT-3 ); GATA4 (5 -GTCATCTCACTACGGGCACA-3  and
5 -CTTCAGGGCCGAGAGGAC-3 ); Oct4 (5 -TGGGCT-
CGAGAAGGATGTG-3  and 5 -GCATAGTCGCTGCTT-
GATCG-3 )a n dβ-actin (5 -CTGAACCCCAAGGCCAAC-
3  and 5 -TAGCACAGCCTGGATAGCAA-3 ).
2.8. Immunocytochemistry. EBs and NPCs were ﬁxed with
4% paraformaldehyde (PFA) (Electron Microscopy Sciences,
Hatﬁeld, PA) at room temperature for 10 minutes. Neurons
were ﬁxed carefully by adding equal volume of 8% PFA into
wells to equal volume of medium and incubated at room
temperature for 10 minutes. Fixed cells were permeabilized
with 0.3% Triton X-100 (Sigma, Cat. No. X100) for 5
minutes and were blocked in blocking buﬀer (5% normalStem Cells International 7
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Figure 6: Analysis of number of TH+ and TUJ+ neurons (A)–(C). Image under phase-contrast microscopy showed plating density of NPCs
atday1inDA1media(5xmagniﬁcation)(A),cellmorphologyatday12(arrowsindicatetheformationofprocesses)(B)10xmagniﬁcation)
and neurons at day 30 during dopaminergic maturation (C) 10x magniﬁcation). (D)–(F), Neurons treated with Pur (D), SAG (E) and Shh
(F) were characterized by immunostaining with TUJ1 (green) and TH (red) and counterstained with DAPI (blue). Scale bar represents
200μm. (G)–(J) Flow cytometry: No TUJ1 and TH immunoreactive NPCs were detected (H), which is comparable to unstained NPCs (G).
In contrast to the population of unstained diﬀerentiated neurons (I), diﬀerentiated cells showed positive immunoreactivity to TUJ1 and TH
(j). (k) Table illustrates percentage of TUJ1 relative to total cells, TH immunoreactive neurons relative to TUJ1 immunoreactive neurons,
and also relative to total cells quantiﬁed using stereology and ﬂow cytometry in control NPCs after dopaminergic maturation.
goat serum, Vector Labs, Burlingame, CA) in 1x Phosphate
buﬀered saline (PBS) (Sigma, Cat. No. P5493) and followed
by incubation with the primary antibody at 4◦C overnight
in 5% normal goat serum and PBS. The following primary
antibodies were used: Nestin (EMD Millipore, Billerica, MA,
Cat. No. MAB5326), 1:200; Sox1 (EMD Millipore, Cat.
No. AB15766), 1:100; Tyrosine Hydroxylase (TH) (PelFreez
Biologicals, Rogers, AR, Cat. No. P40101-0), 1:300; Pax6
(Developmental Studies Hybridoma Bank, Iowa City, IA,
Cat. No. Pax6), 1:20; neuronal class III β-Tubulin (TUJ1)
(Covance, Princeton, NJ, Cat. No. MMS-435P), 1:500, and
secondary antibodies were Alexa Fluor 488 Goat Anti-
Mouse, Alexa Fluor 555 Goat Anti-Mouse, Alexa Fluor 488
Goat Anti-Rabbit, Alexa Fluor 555 Goat Anti-Rabbit (Invit-
rogen) at 1:300. Coverslips were mounted with Vectashield
Mounting Medium with DAPI (Vector Labs). Fluorescent
images were captured on an Eclipse Ti inverted ﬂuorescence
microscope (Nikon Instruments Inc, Melville, NY). Phase
contrast images were taken with a Zeiss Axiovert 25 Inverted
Microscope (Carl Zeiss AG, Oberkochen, Germany).8 Stem Cells International
2.9. Stereological Analysis. Stereological analysis was per-
formed using an Olympus BH2 microscope (Olympus,
Center Valley, PA) with a motorized X-Y stage linked to a
computer-assisted stereological system (Olympus America
Inc.). This comprises a color video camera (CCD-Iris, Sony),
a PC with a high-resolution SVGA monitor, a microcator
(VRZ 401, Heidenhain), and Stereo Investigator (MBF
Bioscience, Williston, VT). Immunostained coverslips were
delineated at 4x magniﬁcation. From a random start posi-
tion, a counting frame was superimposed on the image, and
cells were systematically sampled using a 40x objective lens
(Olympus), with DAPI stained nucleus used as the sampling
unit. A minimum of 200cells was sampled according to the
rules of the optical dissector [24], and the coeﬃcient of error
foreachstereologicalestimatewasbetween0.07and0.1[25].
2.10. Flow Cytometry. After dopaminergic diﬀerentiation,
cells were dissociated with TrypLE Express (Invitrogen, Cat.
No. 12605-028) at 37◦C for 5 minutes, washed with PBS,
centrifuged, resuspended in PBS, and strained through a
70μm cell strainer (BD Biosciences, Cat No. 352350), cen-
trifuged, resuspended, and ﬁxed in 4% PFA in PBS at room
temperature for 10 minutes. Then they were centrifuged,
resuspended, and permeabilized with 0.3% saponin (Sigma,
Cat. No. 47036), incubated with TUJ1 (Covance, 1:100) and
TH (Pel Freez Biologicals, 1:100) on ice for 30 minutes and
washed with washing buﬀer (PBS and 0.03% saponin) once.
Then cells were incubated with APC-conjugated anti mouse
IgG antibody (BD Biosciences, Cat. No. 550826) and PE-
conjugated anti rabbit IgG antibody (BD Biosciences, Cat.
No. 558416) on ice for 30 minutes, washed with washing
buﬀer, and resuspended in PBS. All sorting procedures were
carriedoutusingBDDigitalVantage(BDBiosciences)witha
80μm nozzle. Data were analyzed by FlowJo ﬂow cytometry
software (Version 7.6.4, Tree Star Inc, Ashland, OR). We
compared cell suspension of unstained NPCs and unstained
diﬀerentiated cells as negative control to determine the
threshold for detection of immunoﬂuorescence.
2.11. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism (Version 4, GraphPad Software, San
Diego, CA). Data were analyzed by one-way analysis of
variance (ANOVA). Newman-Keuls post hoc analysis was
employed when diﬀerences were observed in ANOVA testing
(P<0.05). Data were presented as the means + standard
error of the mean (SEM). All results were derived from at
least three independent experiments, except results of cell
line 1679 in Figure 1 and ﬂow cytometry data in Figure 6
were derived from two independent experiments.
3. Results andDiscussion
3.1. Neuronal Diﬀerentiation Using a 5-Stage Embryoid Body
Approach. The majority of published neuronal diﬀerenti-
ation methods describe selected human embryonic stem
cell (hESC) lines such as H9 or I6 and these protocols
were optimized around these cell lines. Despite general
reproducibility across multiple hESC lines, in patient-
speciﬁc human iPSCs consistent reproducibility has not
been demonstrated, posing a challenge for disease modeling
and drug screening. [26–29]. One recent publication points
towards speciﬁc markers such as miR-371-3 and FoxA2 that
could predict a priori the diﬀerentiation potential of iPSCs
or ESCs into the neuronal lineage, which can be relevant for
downstream applications [30].
Our goal was to develop a reliable protocol reproducible
across various patient-speciﬁc iPSC lines. We tested a 5-stage
protocol for neuronal dopaminergic diﬀerentiation that was
originally introduced by Lee and Studer in mouse embryonic
stem cells [18] and subsequently further developed [28, 29].
This protocol involves EB formation for four days, neural
rosette formation, isolation of neural rosettes, and expansion
and PSA-NCAM enrichment using magnetic bead sorting
of neuroprogenitors. A ﬁnal maturation stage utilizes FGF8
and sonic hedgehog (Shh) for the ﬁrst ten days followed by
BDNF, GDNF, B27, and dcAMP in Neurobasal media for
another 20–50 days (Figure 1(a)). We reason that this 5-stage
protocol generating EBs has several advantages in generating
neural precursors that can be easily expanded without loss of
diﬀerentiation potential [31]. Thus, this protocol is suitable
for studying disease-mechanisms at the neuroprogenitor
stage and maintaining potential for derivation of other CNS
cell types [28].
In a control iPSC line, EBs incubated for 4 days in EB
media showed a similar result of neural rosette formation as
described by Swistowski et al., 2009 [28] (data not shown).
When we attempted to derive NPCs from additional iPSCs
derived from controls and patients aﬀected with PD we
observed very little neural rosette formation. Furthermore,
these rosettes were not expandable as NPCs.
Small molecules have been reported to improve directing
ESC/iPSCs into neural lineage [32, 33]. We tested a com-
bination of small molecules: Dor and SB, both of which
have been described for SMAD inhibition. The synergistic
mode of action of inhibitors of SMAD signaling, Noggin
and SB431542, has been reported to rapidly induce neural
conversionofhESCs[15,34].Noggin,abonemorphogenetic
protein (BMP) antagonist, and the small molecule Dor have
similar activities which selectively inhibit the BMP type I
receptors: ALK2, ALK3, and ALK6 and block SMAD1/5/8
phosphorylation [35]. SB has been shown to be a selective
inhibitor of activin receptor-like kinase receptors ALK4,
ALK5, and ALK7 [36].
For successful generation of NPCs, it is crucial to start
with pristine, undiﬀerentiated iPSC cultures. IPSC colonies
should be densely packed show low nucleus to cytoplasma
ratios and have discrete borders and no diﬀerentiation along
the peripheries and/or in the centers of the colonies. In this
protocol, we found that 2mm diameter sized colonies yield
the best results for neural rosette formation (Figure 2(a)).
3.2. Combination of Dorsomorphin and SB431542 Improved
Neural Induction. IPSC colonies were enzymatically treated
with collagenase. After detachment, half of the colonies in
a dish were exposed to 5μM Dor/10μM SB. The otherStem Cells International 9
half was left untreated. The colonies were then cultured
for 4 days in EB media with or without Dor/SB. EBs
cultured in EB media alone showed loose, less compact,
and irregular shapes (Figure 2(b)) while the majority of EBs
treatedwithDor/SBdemonstratedcompact,solidandround
shaped aggregates and had an average size of 350μmi n
diameter (Figure 2(b)). On day 4, media was changed to
NIM media containing N2 media which was freshly made of
diﬀerent individual components. None of the commercially
available N2 supplements showed consistent results (data
not shown). EBs were then plated onto Geltrex-coated
culture dishes on day 6. During days 6–10, neural rosettes
were detected by their characteristic morphology of radially
arranged cells (Figures 3(A)–3(D)). In the early stages of
NIM incubation (approximately days 8–10), neural rosettes
showed darker centers of “ﬂower-shaped” structures with
indiscrete boundary lines (Figures 3(A) and 3(B)). In the
latter incubation with NIM, “ﬂower-shaped” morphologies
were more distinct and edges more clearly deﬁned, shown in
Figures 3(C) and 3(D). Dissected rosettes (Figures 3(E) and
3(F)) that are replated and manually isolated a second time
generate NPC populations of higher purity.
We evaluated neural diﬀerentiation of EBs on day 10
(Figure 1(b)) via immunocytochemistry. Neural markers
Pax6 and Sox1 were used as well as the pluripotent cell
marker Oct4. Pax6 and Sox1 showed positive staining in
attached EB (Figures 3(G) and 3(H)), however, Oct4 showed
no immunoreactivity (data not shown). At the same time
point, the percentage of neural rosettes formed with and
without addition of Dor/SB was quantiﬁed by manually
counting the colonies containing neural rosettes divided by
total colonies attached on the culture dish (Figures 1(b) and
3(I)). Without Dor/SB, we observed low rosette formation
between 0% and 31.9%, and we were not able to derive
expandable NPCs. The combination of Dor/SB, on the other
hand, increased the neural rosette formation substantially to
48% to 97.5% of EBs in both control and PD-speciﬁc cell
lines. Overall, we did not notice a diﬀerence in the eﬃciency
of rosette formation between PD lines and control lines.
At day 6, we performed gene expression analysis of
multiple markers in attached EBs. In all six lines we studied
neuroectodermal markers Sox1 and Nestin, mesodermal
marker Brachyury, endodermal marker GATA4 and pluripo-
tentmarkerOct4.Surprisingly,therewasastrikingdiﬀerence
of >150-fold in the gene expressions of neuroectodermal
markers Sox1 and Nestin in Dor-/SB-treated EBs compared
to EBs without small molecules (Figure 4). This suggests
that the two small molecules very eﬃciently modulate
the SMAD signaling pathway leading to this enormous
increase in neuroectodermal markers. This increase was
consistent in all six iPSC lines tested, and diﬀerences in
neuronal diﬀerentiation were not observed between patient
and control lines. Endo and mesodermal markers GATA4
a n dB r a c h y u r ya sw e l la sp l u r i p o t e n c ym a r k e rO c t4w e r e
all lower compared to the untreated, normalized NPC
lines.
Neural rosettes were manually cut and replated as pieces
to produce a population of NPCs of higher purity. Rosettes
were manually isolated once again, collected, enzymatically
treated with Accutase, and plated and expanded in NPC
media.ManualpassagingandexpansionofNPCsstillyielded
approximately 10% undiﬀerentiated Oct4-positive cells in
NPC cultures, which upon further expansion showed iPSC
morphology (data not shown). Therefore, we used magnetic
bead sorting with a neural cell adhesion molecule antibody
against polysialic acid neural cell adhesion molecule (PSA-
NCAM or CD56) (Figures 5(A) and 5(B)). We observed an
approximately 20% cell loss after magnetic bead sorting. We
characterized NPCs after sorting by immunocytochemistry
with deﬁned markers Nestin and Sox1. We detected >90%
Nestin and Sox1 immunoreactive NPCs in all iPSC cell lines
taken through this protocol (Figures 5(C) and 5(D)). NPCs
were readily expandable at a passaging ratio of 1:2 to 1:3
with Accutase. Cultures grew well when media was prepared
freshlyevery2to3daysandB27addedfreshlytoNPCmedia,
before media changes. We expanded NPC cultures for >15
passages after derivation and did not observe any changes in
morphology or expression of Nestin and Sox1.
With this new approach for neural induction using small
molecules, we have dramatically increased reproducibility
and eﬃciency of neural rosette stage/NPC generation. This
is invaluable when using patient-derived iPSCs for disease
modeling, which may have an intrinsic disadvantage in
culture when carrying potential disease-related deﬁciencies.
Since NPCs can be easily expanded, this could become a
suitable cell type for high throughput screening where a very
large number of starting material is needed.
3.3. Substitution of Small Molecules Purmorphamine or
Smoothened Agonist for Sonic Hedgehog Had Similar Eﬀects
on Neuronal Maturation. We investigated the substitution of
sonic hedgehog (Shh) for small molecules purmorphamine
(Pur) or smoothened agonist (SAG) during dopaminergic
maturation. These chemicals that are considerably less
expensive, have minimal lot-to-lot variabilities, and have
longer shelf-life compared to recombinant proteins.
For ﬁnal dopaminergic maturation, we used a 2-step
approach. For the ﬁrst ten days, we cultured NPCs in
FGF8 and tested two small molecules SAG and Pur as
substitutes for Shh in control and patient cell lines. At day
1 in DA1 media, the plating density of the NPCs should
be approximately 60% to 70% (Figure 6(A)). During this
10-day protocol, cells were split at 100% conﬂuency using
Accutase and replated at a cell density of approximately
80%. When cells were plated at a lower cell density (<50%),
we observed remarkable cell death and low rates of cell
attachment. After ten days, we switched to Neurobasal media
supplemented with BDNF, GDNF, dcAMP, and B27 every
second day, but added B27 daily preventing cell death.
Cells were split until they began growing out processes
(Figure 6(B)). After day 30 of dopaminergic maturation,
cells were ﬁxed, immunostained with TUJ1 and TH, and
counterstained with DAPI (Figures 6(C)–6(F)).
To measure the eﬃciency of the neuronal diﬀerentiation,
we evaluated the percentage of TH and TUJ1 expressing neu-
rons relative to total cells using two approaches: stereology
with systematic random sampling and ﬂow cytometry. Flow
cytometry was employed to minimize bias. The challenges of10 Stem Cells International
accurate counting of these cultures are the dense “patches”
of neurons and the majority of TH immunoreactive neurons
localized in these “patches” [37].
In the scatter plots for ﬂow cytometry, (Figures 6(G)–
6(J)),undiﬀerentiatedNPCsdidnotshowimmunoreactivity
for TUJ1 and TH (Figure 6(H)) and had a similar pattern
in the scatter plot to unstained NPCs (Figure 6(G)). Diﬀer-
entiated neurons were immunoreactive for TUJ1 and TH
(Figure 6(I)) and were compared to the total number of
unstained diﬀerentiated neurons (Figure 6(J)).
Both approaches, stereology and ﬂow cytometry, showed
no signiﬁcant diﬀerences among the three diﬀerent compo-
nents Shh, SAG, or Pur used in dopaminergic diﬀerentiation
in terms of the ratio of TUJ1/total, TH/TuJ1, and TH/total
cells (Figure 6(K)). Data from ﬂow cytometry was slightly
lowerthanthosefromthestereologicalapproach.Wesuspect
that we lost neurons during the handling process such as
dissociation and passaging through a cell strainer to ﬁlter
clumps from cell suspension before ﬂow cytometry was
performed.
Some studies have shown that with an extension of
culturing time by up to 60 days, more neurons convert
to TH-positive as well as become electrophysiologically
mature [37, 38]. Other studies showed a higher percentage
of TH-positive neurons, however, diﬀerent quantiﬁcation
approaches may have introduced bias toward a higher
percentage of neuronal yields.
4. Discussion:Small Molecules for Efﬁcient
Neuronal Differentiation
Over the last few years, there has been an enormous
push to optimize diﬀerentiation protocols with diﬀerent
small molecules and screens to identify new factors that
would modulate and improve neuronal diﬀerentiation and
maturation.
Other small molecules and compounds have been
identiﬁed for the enhancement of neuronal diﬀerentiation.
Glycogen synthase kinase-3 (GSK-3) inhibitors such as
kenpaullone or SB-216763 have been shown to positively
impact the neuronal diﬀerentiation of neural progenitor
c e l l sw i t h o u tc h a n g i n gc e l lc y c l ee x i to rc e l ls u r v i v a l[ 39].
Furthermore, GSK-3 inhibitors showed protection against
excitotoxicity, mediated by NMDAandnon-NMDA receptor
agonists, in cultured rat primary cerebellar granule neuronal
cultures from the cerebellum and hippocampus [40].
(+)-Cholesten-3-one but not cholesterol has been shown
to eﬀectively promote the activity of the TH promoter.
(+)-Cholesten-3-one has also been shown to induce diﬀer-
entiation of neuroprogenitors into dopaminergic neurons
monitored by expression of TH, dopamine transporter,
dopa decarboxylase, and higher levels of dopamine secretion
[41].
Neurosteroids are thought to aﬀect neuronal survival,
neurite outgrowth, and neurogenesis both in vivo and in
vitro [42], that is, progesterone [43] and estradiol [44]. Pro-
gesterone added at the neural proliferation stage increased
the number of dopaminergic neurons, whereas progesterone
added during ﬁnal diﬀerentiation did not induce signiﬁcant
changes in the number of dopaminergic neurons generated.
Interestingly, this eﬀect was not mediated by the activation
of progesterone receptors because RU 486 did not block
the eﬀects of progesterone on dopaminergic diﬀerentiation
[43]. It has also been shown that estradiol can increase the
generation of dopaminergic precursors expressing Lmx1a
and can induce formation of a higher percentage of mature
dopaminergic neurons [44].
In addition, polyunsaturated fatty acids such as arachi-
donic acid (ARA) and docosahexaenoic acid (DHA) have
been shown to have critical roles in brain development and
function and can promote neurogenesis [45]. Speciﬁcally,
DHA, a ligand for the RXR/Nurr1 heterodimer, can activate
the Nurr1 gene in iPSCs. It has been shown that DHA
facilitates iPSC diﬀerentiation into TH-positive neurons in
vitro as well as in vivo [46].
Through a peptide library screen a novel small syn-
thetic peptide Cripto BP was discovered to block Cripto,
a glycosylphosphatidylinositol-anchored coreceptor. It has
been shown that this receptor binds Nodal and the ALK-4
receptors and promotes cardiac diﬀerentiation. The deletion
or inhibition of Cripto leads to a promotion of neuronal and
midbrain diﬀerentiation of mouse embryonic stem cells. The
synthetic peptide Cripto BP can mimic this eﬀect [47].
5. Conclusion
Small molecules can enhance various steps of neuronal
diﬀerentiation into dopaminergic neurons and can replace
expensive recombinant proteins that were initially used in
the pioneering protocols. However, there is still a need for
improvement of diﬀerentiation protocols that increase the
number and region-speciﬁcity of mature region speciﬁc
dopaminergic neurons, but selective inhibitors and other
small molecules might change the ﬁeld and reduce the
cost.
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